Reponex Pharmaceuticals A/S is the first biotech company since 2017 to be admitted to trading on Nasdaq Copenhagen, and will after completion will be a subsidiary of Pharma Equity Group A/S.
Accura has assisted Pharma Equity Group A/S in connection with the IPO of Reponex Pharmaceuticals A/S, including in connection with approval of the prospectus issued in connection with the issuance of 977,347,625 new (consideration)shares at price of DKK 1.57 per share, corresponding to a total subscription amount of approx. DKK 1.5bn. The shares will be issued to the shareholders of Reponex Pharmaceuticals A/S as consideration for their shares in Reponex Pharmaceuticals A/S.
In addition to the issuance of the consideration shares, a rights issue will be carried out in Pharma Equity Group A/S and the shares in the previously issued b-share class in Pharma Equity Group A/S will be admitted to trading and official listing. The first trading day for the new shares is expected to be 28 March 2023.
Reponex Pharmaceuticals A/S is a Danish biopharmaceutical company that develops medicines based on known active pharmaceutical ingredients that are already used in other medicines. This means faster and cheaper development of medicines with lower risk, since the side effects of the ingredients are already known and described.
Accura advised Pharma Equity Group A/S in connection with the IPO.